Competition Commission of India (CCI) has given its nod to Pfizer-Piramal where Piramal Enterprises’ proposed acquisition of four brands from pharmaceutical major Pfizer.
As per the deal announced in May, Piramal Enterprises’ consumer products division entered into an agreement to acquire Ferradol, Neko, Sloan’s and Waterbury’s Compound brands for a consideration of Rs 110 crore. The deal also included trademark rights for Ferradol and Waterbury’s Compound in Bangladesh and Sri Lanka.
Pfizer has produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections.
